Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study
Background Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-...
Saved in:
| Published in: | Supportive care in cancer Vol. 30; no. 8; pp. 6583 - 6591 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.08.2022
Springer Springer Nature B.V |
| Subjects: | |
| ISSN: | 0941-4355, 1433-7339, 1433-7339 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients.
Method
This multicenter (
n
= 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom.
Results
Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60–76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36–48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57–78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55–75%).
Conclusion
The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. |
|---|---|
| AbstractList | Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients.
This multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom.
Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60-76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36-48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57-78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55-75%).
The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients. This multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom. Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60-76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required [greater than or equal to] 1 dose interruption, and 29% experienced [greater than or equal to] 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36-48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57-78%)] had a mDI [greater than or equal to] than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55-75%). The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients.BACKGROUNDTyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients.This multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom.METHODThis multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom.Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60-76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36-48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57-78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55-75%).RESULTSEighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60-76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36-48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57-78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55-75%).The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials.CONCLUSIONThe AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. Background Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients. Method This multicenter ( n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom. Results Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60–76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36–48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57–78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55–75%). Conclusion The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. Abstract Background Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients.MethodThis multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom.ResultsEighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60–76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36–48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57–78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55–75%).ConclusionThe AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. Background Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients. Method This multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom. Results Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60-76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required [greater than or equal to] 1 dose interruption, and 29% experienced [greater than or equal to] 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36-48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57-78%)] had a mDI [greater than or equal to] than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55-75%). Conclusion The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials. |
| Audience | Academic |
| Author | Geoffrois, Lionnel Barthelemy, Philippe Malouf, Gabriel Bigot, Cécile Schuster, Caroline Lang, Hervé Gaillard, Victor Fritsch, Aurélie Trensz, Philippe Lhuillier, Albane Pierard, Laure Borchiellini, Delphine Tricard, Thibault Burgy, Mickael |
| Author_xml | – sequence: 1 givenname: Victor orcidid: 0000-0003-1586-3995 surname: Gaillard fullname: Gaillard, Victor email: victor.gaillard@chru-strasbourg.fr organization: Department of Urology, University Hospital – sequence: 2 givenname: Albane surname: Lhuillier fullname: Lhuillier, Albane organization: Department of Medical Oncology, Institut de Cancérologie de Lorraine (ICL) – sequence: 3 givenname: Cécile surname: Bigot fullname: Bigot, Cécile organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 4 givenname: Laure surname: Pierard fullname: Pierard, Laure organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 5 givenname: Philippe surname: Trensz fullname: Trensz, Philippe organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 6 givenname: Mickael surname: Burgy fullname: Burgy, Mickael organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 7 givenname: Caroline surname: Schuster fullname: Schuster, Caroline organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 8 givenname: Gabriel surname: Malouf fullname: Malouf, Gabriel organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 9 givenname: Aurélie surname: Fritsch fullname: Fritsch, Aurélie organization: Institut de Cancérologie Strasbourg Europe (ICANS) – sequence: 10 givenname: Hervé surname: Lang fullname: Lang, Hervé organization: Department of Urology, University Hospital – sequence: 11 givenname: Thibault surname: Tricard fullname: Tricard, Thibault organization: Department of Urology, University Hospital – sequence: 12 givenname: Delphine surname: Borchiellini fullname: Borchiellini, Delphine organization: Department of Medical Oncology, Centre Antoine Lacassagne – sequence: 13 givenname: Lionnel surname: Geoffrois fullname: Geoffrois, Lionnel organization: Department of Medical Oncology, Institut de Cancérologie de Lorraine (ICL) – sequence: 14 givenname: Philippe surname: Barthelemy fullname: Barthelemy, Philippe organization: Institut de Cancérologie Strasbourg Europe (ICANS) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35484315$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u3CAUha0qVTNJ-wJdVEjddOMUAzZ2Vx1F_YkaKZvsEQPXEyIbXMCJ5jX7RL2eSRs1qiIkEPCdw9XlnBRHPngoircVPasolR8TpTWjJWWspJK2bVm9KFaV4LyUnHdHxYp2oioFr-vj4iSlW0orKWv2qjjmtWgFr-pV8etinLTJJPQk3wDR01RudAJLtLfEzzFBOeAuzdMUYnZ3QIyOQKYYtlGPZP3j6rMNIwme2JCAOJ_BJ5d3i2GIeiizjlvIaIH2UU8OEkJk0tmBz4ncu3xDRsg6ZTwyJILXAzEw4KS9gfiJaDLOA94hH5EImwTxDuGwkBFyDGkCs68t5dnuXhcvez0kePOwnhbXX79cn38vL6--XZyvL0sjBMslWAm14MawjWiMZbZvdAOm4cxU0IGptRW9ZFQ2pml72-Jt1fa16FlNu0bw0-LDwRZ78XOGlNXo0lK49hDmpFhTt4yzljeIvn-C3oY5YvkLJduulZ1kj9RWD6Cc70OO2iymai2p7PDDOonU2X8oHBZGZzAgvcPzfwTvHh6fNyNYNUU36rhTfzKAADsABjuZIvR_kYqqJWjqEDSFQVP7oKkKRe0TkXF5_ylYjhuel_KDNOE7fgvxsRvPqH4DiG3qkw |
| CitedBy_id | crossref_primary_10_1016_j_clgc_2023_11_001 crossref_primary_10_1080_14740338_2022_2153115 crossref_primary_10_1016_j_therap_2024_04_001 crossref_primary_10_1007_s40262_025_01504_5 |
| Cites_doi | 10.1056/NEJMoa1803675 10.1002/jcph.73 10.1016/S1470-2045(13)70464-9 10.1056/NEJMoa1303989 10.1002/cam4.302 10.1016/j.purol.2009.05.009 10.1016/j.ejca.2020.09.030 10.1016/j.eururo.2018.08.036 10.1634/theoncologist.2018-0787 10.1016/j.ejca.2017.04.015 10.2196/19685 10.1016/S1470-2045(12)70559-4 10.1016/S1470-2045(19)30413-9 10.1002/pds.4228 10.1007/s12032-012-0236-6 10.1038/bjc.2015.368 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. COPYRIGHT 2022 Springer The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 – notice: 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. – notice: COPYRIGHT 2022 Springer – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. |
| DBID | AAYXX CITATION NPM 0-V 3V. 7RV 7X7 7XB 88E 88J 8AO 8FI 8FJ 8FK ABUWG AFKRA ALSLI AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HEHIP K9. KB0 M0S M1P M2R M2S NAPCQ PHGZM PHGZT PJZUB PKEHL POGQB PPXIY PQEST PQQKQ PQUKI PRINS PRQQA Q9U 7X8 |
| DOI | 10.1007/s00520-022-07088-1 |
| DatabaseName | CrossRef PubMed ProQuest Social Sciences Premium Collection【Remote access available】 ProQuest Central (Corporate) Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Social Science Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Social Science Premium Collection ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Sociology Collection (OCUL) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Social Science Database Sociology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest Sociology & Social Sciences Collection One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China One Social Sciences ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Sociology & Social Sciences Collection ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Social Science Journals (Alumni Edition) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Sociology & Social Sciences Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Sociology Collection ProQuest Central (New) ProQuest Sociology ProQuest Medical Library (Alumni) Social Science Premium Collection ProQuest One Social Sciences ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Sociology Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Social Science Journals ProQuest Medical Library ProQuest Social Sciences Premium Collection ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ProQuest Sociology & Social Sciences Collection |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Nursing |
| EISSN | 1433-7339 |
| EndPage | 6591 |
| ExternalDocumentID | A707943197 35484315 10_1007_s00520_022_07088_1 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 0-V 04C 06C 06D 0R~ 0VY 123 1N0 1SB 2.D 203 28- 29Q 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALSLI ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARALO ARMRJ ASOEW ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS ECF ECT EIHBH EIOEI EJD EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HEHIP HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IXE IZIGR IZQ I~X I~Z J-C J0Z J5H JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M2R M2S M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB POGQB PPXIY PRQQA NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c442t-ed7e543cc2b46cd2df6a6ec632c1e9ec5ad4f72076c68fd86a618f54f2509643 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000788451900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0941-4355 1433-7339 |
| IngestDate | Sun Nov 09 09:50:25 EST 2025 Sat Nov 15 13:11:52 EST 2025 Sat Nov 29 14:02:46 EST 2025 Sat Nov 29 10:36:09 EST 2025 Wed Feb 19 02:26:13 EST 2025 Sat Nov 29 06:39:54 EST 2025 Tue Nov 18 21:31:35 EST 2025 Fri Feb 21 02:46:43 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | App-based program TKI Supportive care program Nurse-led program Kidney cancer |
| Language | English |
| License | 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-ed7e543cc2b46cd2df6a6ec632c1e9ec5ad4f72076c68fd86a618f54f2509643 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-1586-3995 |
| PMID | 35484315 |
| PQID | 2678987972 |
| PQPubID | 326297 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2658232836 proquest_journals_2678987972 gale_infotracmisc_A707943197 gale_infotracacademiconefile_A707943197 pubmed_primary_35484315 crossref_primary_10_1007_s00520_022_07088_1 crossref_citationtrail_10_1007_s00520_022_07088_1 springer_journals_10_1007_s00520_022_07088_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-01 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Supportive care in cancer |
| PublicationTitleAbbrev | Support Care Cancer |
| PublicationTitleAlternate | Support Care Cancer |
| PublicationYear | 2022 |
| Publisher | Springer Berlin Heidelberg Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer – name: Springer Nature B.V |
| References | Global Cancer Observatory [Internet] (2021). Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed 16 Apr 2021 CapitanioUBensalahKBexABoorjianSABrayFColemanJEpidemiology of renal cell carcinomaEur Urol2019751748410.1016/j.eururo.2018.08.036 KawashimaATsujimuraATakayamaHAraiYNinMTanigawaGImportance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma : the Osaka Renal Cell Carcinoma Clinical Study CollaborationMed Oncol2012295329833051:CAS:528:DC%2BC38XhslCnsbbE10.1007/s12032-012-0236-6 RiniBIMelicharBUedaTGrünwaldVFishmanMNArranzJAAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialLancet Oncol20131412123312421:CAS:528:DC%2BC3sXhslWlsbjK10.1016/S1470-2045(13)70464-9 AudenetFRouprêtMMéjeanACancer du rein et thérapies ciblées : controverses sur les prises en charge thérapeutiquesProg Urol20091995966051:STN:280:DC%2BD1MnmslSktw%3D%3D10.1016/j.purol.2009.05.009 AlbigesLFléchonAChevreauCTopartDGravisGOudardSReal-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access ProgramEur J Cancer20211421021111:CAS:528:DC%2BB3cXitlent7%2FO10.1016/j.ejca.2020.09.030 GirgisADurcinoskaIArnoldADescallarJKaadanNKohE-SWeb-Based Patient-Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care): multicenter pragmatic nonrandomized trialJ Med Internet Res.20202210e1968510.2196/19685 NoizePGrelaudABayJ-OChevreauCGross-GoupilMCulineSReal-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study: Sunitinib in First-line Therapy of mRCCPharmacoepidemiol Drug Saf20172612156115691:CAS:528:DC%2BC2sXhvFemsb3M10.1002/pds.4228 MotzerRJRiniBIMcDermottDFArén FronteraOHammersHJCarducciMANivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialLancet Oncol20192010137013851:CAS:528:DC%2BC1MXhsF2rurfM10.1016/S1470-2045(19)30413-9 HengDYXieWReganMMHarshmanLCBjarnasonGAVaishampayanUNExternal validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyLancet Oncol201314214114810.1016/S1470-2045(12)70559-4 Motzer RJ, Reeves J, Nathan P, Merchan JR, Jin J, Harmenberg U, et al. (2013) Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. N Engl J Med. 10. Ljungberg B, Albiges L, Bedke J, Bex A, Capitanio U, Giles RH et al (2020) EAU Guidelines on renal cell carcinoma [Internet]. Available at: https://uroweb.org/guidelines/renal-cell-carcinoma. Accessed 20 Apr 2022 SchmidingerMBamiasAProcopioGHawkinsRSanchezARVázquezSProspective observational study of pazopanib in patients with advanced renal cell carcinoma (PRINCIPAL Study)Oncol20192444914971:CAS:528:DC%2BC1MXhtFaqsbrK10.1634/theoncologist.2018-0787 MatiasMLe TeuffGAlbigesLGuidaABrardCBacciareloGReal world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centreEur J Cancer2017791851921:CAS:528:DC%2BC2sXntlWltLs%3D10.1016/j.ejca.2017.04.015 DonskovFMichaelsonMDPuzanovIDavisMPBjarnasonGAMotzerRJSunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsBr J Cancer201511311157115801:CAS:528:DC%2BC2MXhslWlu7fL10.1038/bjc.2015.368 RiniBIGarrettMPolandBDutcherJPRixeOWildingGAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis: The Journal of Clinical PharmacologyJ Clin Pharmacol20135354915041:CAS:528:DC%2BC2cXhs1yntrbP10.1002/jcph.73 Barthelemy P. ASCO GU 2020: prospective observational study on pazopanib in patients treated for advanced/metastatic renal cell carcinoma: APOLON Study [Internet]. Available at: https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119277-asco-gu-2020-prospective-observational-study-on-pazopanib-in-patients-treated-for-advanced-metastatic-renal-cell-carcinoma-apolon-study.html. Accessed 29 Oct 2020 MéjeanARavaudAThezenasSColasSBeauvalJ-BBensalahKSunitinib alone or after nephrectomy in metastatic renal-cell carcinomaN Engl J Med.201837954172710.1056/NEJMoa1803675 PortaCLevyAHawkinsRCastellanoDBellmuntJNathanPImpact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCancer Med201436151715261:CAS:528:DC%2BC2MXhsFOmsQ%3D%3D10.1002/cam4.302 7088_CR1 F Audenet (7088_CR3) 2009; 19 F Donskov (7088_CR11) 2015; 113 7088_CR13 P Noize (7088_CR15) 2017; 26 A Girgis (7088_CR19) 2020; 22 C Porta (7088_CR8) 2014; 3 7088_CR16 A Méjean (7088_CR4) 2018; 379 M Matias (7088_CR18) 2017; 79 L Albiges (7088_CR14) 2021; 142 A Kawashima (7088_CR10) 2012; 29 RJ Motzer (7088_CR7) 2019; 20 M Schmidinger (7088_CR17) 2019; 24 U Capitanio (7088_CR2) 2019; 75 DY Heng (7088_CR6) 2013; 14 BI Rini (7088_CR12) 2013; 14 7088_CR5 BI Rini (7088_CR9) 2013; 53 |
| References_xml | – reference: Global Cancer Observatory [Internet] (2021). Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed 16 Apr 2021 – reference: RiniBIMelicharBUedaTGrünwaldVFishmanMNArranzJAAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialLancet Oncol20131412123312421:CAS:528:DC%2BC3sXhslWlsbjK10.1016/S1470-2045(13)70464-9 – reference: Barthelemy P. ASCO GU 2020: prospective observational study on pazopanib in patients treated for advanced/metastatic renal cell carcinoma: APOLON Study [Internet]. Available at: https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119277-asco-gu-2020-prospective-observational-study-on-pazopanib-in-patients-treated-for-advanced-metastatic-renal-cell-carcinoma-apolon-study.html. Accessed 29 Oct 2020 – reference: CapitanioUBensalahKBexABoorjianSABrayFColemanJEpidemiology of renal cell carcinomaEur Urol2019751748410.1016/j.eururo.2018.08.036 – reference: NoizePGrelaudABayJ-OChevreauCGross-GoupilMCulineSReal-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study: Sunitinib in First-line Therapy of mRCCPharmacoepidemiol Drug Saf20172612156115691:CAS:528:DC%2BC2sXhvFemsb3M10.1002/pds.4228 – reference: RiniBIGarrettMPolandBDutcherJPRixeOWildingGAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis: The Journal of Clinical PharmacologyJ Clin Pharmacol20135354915041:CAS:528:DC%2BC2cXhs1yntrbP10.1002/jcph.73 – reference: MéjeanARavaudAThezenasSColasSBeauvalJ-BBensalahKSunitinib alone or after nephrectomy in metastatic renal-cell carcinomaN Engl J Med.201837954172710.1056/NEJMoa1803675 – reference: HengDYXieWReganMMHarshmanLCBjarnasonGAVaishampayanUNExternal validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyLancet Oncol201314214114810.1016/S1470-2045(12)70559-4 – reference: DonskovFMichaelsonMDPuzanovIDavisMPBjarnasonGAMotzerRJSunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsBr J Cancer201511311157115801:CAS:528:DC%2BC2MXhslWlu7fL10.1038/bjc.2015.368 – reference: AlbigesLFléchonAChevreauCTopartDGravisGOudardSReal-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access ProgramEur J Cancer20211421021111:CAS:528:DC%2BB3cXitlent7%2FO10.1016/j.ejca.2020.09.030 – reference: Motzer RJ, Reeves J, Nathan P, Merchan JR, Jin J, Harmenberg U, et al. (2013) Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. N Engl J Med. 10. – reference: GirgisADurcinoskaIArnoldADescallarJKaadanNKohE-SWeb-Based Patient-Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care): multicenter pragmatic nonrandomized trialJ Med Internet Res.20202210e1968510.2196/19685 – reference: MotzerRJRiniBIMcDermottDFArén FronteraOHammersHJCarducciMANivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialLancet Oncol20192010137013851:CAS:528:DC%2BC1MXhsF2rurfM10.1016/S1470-2045(19)30413-9 – reference: AudenetFRouprêtMMéjeanACancer du rein et thérapies ciblées : controverses sur les prises en charge thérapeutiquesProg Urol20091995966051:STN:280:DC%2BD1MnmslSktw%3D%3D10.1016/j.purol.2009.05.009 – reference: SchmidingerMBamiasAProcopioGHawkinsRSanchezARVázquezSProspective observational study of pazopanib in patients with advanced renal cell carcinoma (PRINCIPAL Study)Oncol20192444914971:CAS:528:DC%2BC1MXhtFaqsbrK10.1634/theoncologist.2018-0787 – reference: PortaCLevyAHawkinsRCastellanoDBellmuntJNathanPImpact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCancer Med201436151715261:CAS:528:DC%2BC2MXhsFOmsQ%3D%3D10.1002/cam4.302 – reference: KawashimaATsujimuraATakayamaHAraiYNinMTanigawaGImportance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma : the Osaka Renal Cell Carcinoma Clinical Study CollaborationMed Oncol2012295329833051:CAS:528:DC%2BC38XhslCnsbbE10.1007/s12032-012-0236-6 – reference: MatiasMLe TeuffGAlbigesLGuidaABrardCBacciareloGReal world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centreEur J Cancer2017791851921:CAS:528:DC%2BC2sXntlWltLs%3D10.1016/j.ejca.2017.04.015 – reference: Ljungberg B, Albiges L, Bedke J, Bex A, Capitanio U, Giles RH et al (2020) EAU Guidelines on renal cell carcinoma [Internet]. Available at: https://uroweb.org/guidelines/renal-cell-carcinoma. Accessed 20 Apr 2022 – ident: 7088_CR5 – volume: 379 start-page: 417 issue: 5 year: 2018 ident: 7088_CR4 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1803675 – volume: 53 start-page: 491 issue: 5 year: 2013 ident: 7088_CR9 publication-title: J Clin Pharmacol doi: 10.1002/jcph.73 – volume: 14 start-page: 1233 issue: 12 year: 2013 ident: 7088_CR12 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70464-9 – ident: 7088_CR16 doi: 10.1056/NEJMoa1303989 – volume: 3 start-page: 1517 issue: 6 year: 2014 ident: 7088_CR8 publication-title: Cancer Med doi: 10.1002/cam4.302 – volume: 19 start-page: 596 issue: 9 year: 2009 ident: 7088_CR3 publication-title: Prog Urol doi: 10.1016/j.purol.2009.05.009 – volume: 142 start-page: 102 year: 2021 ident: 7088_CR14 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.09.030 – volume: 75 start-page: 74 issue: 1 year: 2019 ident: 7088_CR2 publication-title: Eur Urol doi: 10.1016/j.eururo.2018.08.036 – volume: 24 start-page: 491 issue: 4 year: 2019 ident: 7088_CR17 publication-title: Oncol doi: 10.1634/theoncologist.2018-0787 – volume: 79 start-page: 185 year: 2017 ident: 7088_CR18 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.04.015 – volume: 22 start-page: e19685 issue: 10 year: 2020 ident: 7088_CR19 publication-title: J Med Internet Res. doi: 10.2196/19685 – ident: 7088_CR1 – volume: 14 start-page: 141 issue: 2 year: 2013 ident: 7088_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70559-4 – volume: 20 start-page: 1370 issue: 10 year: 2019 ident: 7088_CR7 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30413-9 – ident: 7088_CR13 – volume: 26 start-page: 1561 issue: 12 year: 2017 ident: 7088_CR15 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4228 – volume: 29 start-page: 3298 issue: 5 year: 2012 ident: 7088_CR10 publication-title: Med Oncol doi: 10.1007/s12032-012-0236-6 – volume: 113 start-page: 1571 issue: 11 year: 2015 ident: 7088_CR11 publication-title: Br J Cancer doi: 10.1038/bjc.2015.368 |
| SSID | ssj0017752 |
| Score | 2.3858838 |
| Snippet | Background
Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and... Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal... Background Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and... Abstract Background Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6583 |
| SubjectTerms | Antimitotic agents Antineoplastic agents Cancer Care and treatment Chemotherapy Clinical research Clinical trials Complications and side effects Critical incidents Discontinued Dosage Drug dosages Elementary school students Inhibitor drugs Kidney cancer Medical personnel Medical treatment Medicine Medicine & Public Health Metastasis Nurse led services Nurses Nursing Nursing care Nursing Research Oncology Oncology, Experimental Oral administration Original Article Pain Medicine Palliative care Patients Rehabilitation Medicine Side effects Targeted cancer therapy |
| SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIMSF9yNQkJGQOIBV4sSPcIEVogIBhUMPe4sc25FWapOQZJH4m_wiZhwnZSvRC8eVJ7OO8nnGY38zQ8hzcMlWF5VlrvYeAhRTMS0ryQqreWq9M2Yqmf9FHR3p9br4Hg_chkirnG1iMNSutXhGfsDBqkJ8XCj-tvvBsGsU3q7GFhqXyRVsm404V-sl4EqVCh13IIKBOAkca0yaCalzgQDCkMsOoAe0pDuO6bx5_ss_nbswDX7o8Ob_vsEtciPuQOlqgsxtcsk3d8i1r_GO_S75_SkkTtK2prA5pKbrGLo6R03jaOB8sBP4NWw73LqDsaTIHqOR6EVXn7-9c-0pbRvq2sHTzcSRH3-hQiwHwCbyOaiYcr8gVAchGgu8DhRPhumpHw3mOm0s7T1OFy8Y4I8Aov0bamjgQQZiKUi01XK0DJK9H_t2TiCloXzuPXJ8-OH4_UcWOz8wm-d8ZN4pL_LMWl7l0jruammktzLjNvWFt8K4vFb8tZJW6tppGE11LfKaYzWbPLtP9pq28Q8J1WmW60xzww34a2ELIRR3Xjghc1k5k5B0_uqljVXRsTnHSbnUcw5IKQEpZUBKmSbk5fJMN9UEuVD6BYKpRIMBmq2JeQ8wPyy9Va6wRiFs4wqVkP0dSVjodnd4xlUZDc1QnoEqIc-WYXwSyXONb7coIzRsnHUmE_JggvEy7wwiVtAuEvJqxvWZ8n-_1KOL5_KYXOdhaSFRcp_sjf3WPyFX7c9xM_RPwyL9A_pVRNk priority: 102 providerName: ProQuest |
| Title | Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study |
| URI | https://link.springer.com/article/10.1007/s00520-022-07088-1 https://www.ncbi.nlm.nih.gov/pubmed/35484315 https://www.proquest.com/docview/2678987972 https://www.proquest.com/docview/2658232836 |
| Volume | 30 |
| WOSCitedRecordID | wos000788451900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1433-7339 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0017752 issn: 0941-4355 databaseCode: 7RV dateStart: 20220101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1433-7339 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0017752 issn: 0941-4355 databaseCode: BENPR dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1433-7339 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0017752 issn: 0941-4355 databaseCode: 7X7 dateStart: 20220101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Social Science Database customDbUrl: eissn: 1433-7339 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0017752 issn: 0941-4355 databaseCode: M2R dateStart: 20220101 isFulltext: true titleUrlDefault: https://search.proquest.com/socscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Sociology Database customDbUrl: eissn: 1433-7339 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0017752 issn: 0941-4355 databaseCode: M2S dateStart: 20220101 isFulltext: true titleUrlDefault: https://search.proquest.com/sociology providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1433-7339 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017752 issn: 0941-4355 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9QwDI9gA8TLgPGvY5yChMQDVKJpm6Q87UCbQLBjuk3TvVVpkkonbe2p7SHxNflE2GnacRMgwUukKq4vJ7uxHf_sEPISTLKWWaFDU1oLAYoqQskLHmZaskhbo1TfMv-LmM3kYpGd-KKwdkC7DylJt1OPxW4OshEi-hzUFOQLMc82mDuJFzbMT8_H3IEQ7p4diFsgOgJz6ktlfs9jwxxd35R_sUrX0qTO-hzd-7913yc73tuk0149HpAbttold459Pn2X3PaHBQ_Jj0-uXJLWJQWXkKrVKkQDZ6iqDHVIj_ACntr1Ch122CIpYsaoh3fR6eevB6a-pHVFTd1auuyR8d13ZIhNAMIecg4s-oovCNCBiPq2ri3F82B6aTuFFU5LTRuLC8e0AvwQKGbzjirq0I8OTgoUdTEeKANlY7umHspGqWua-4icHR2effgY-vseQp0krAutETZNYq1ZkXBtmCm54lbzmOnIZlanyiSlYG8F11yWRsJsJMs0KRn2sEnix2Srqiv7lFAZxYmMJVNMgZVOdZamghmbmpQnvDAqINEg9Vz7Xuh4JcdFPnZxdlLLQWq5k1oeBeT1-M6q7wTyV-pXqEw5bhPAWStf7QDrw4Zb-RQ7E4LzlomA7G9QwuetN6cHdcz99tLmDFyMTIpMsIC8GKfxTYTMVbZeI00qwV2WMQ_Ik16Nx3XHEKcC9zQgbwadvWL-5z-192_kz8hd5tQe4ZL7ZKtr1vY5uaW_dcu2mZCbYn6O40K4UU7I9vvD2ckcno5ZP55O3Kf9E-q0Q9U |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQZQLb0qggJFAHIqF4rwcJAQroOpqHyC0h94sx3akldpkSbKg_ij-DL-IGedRthK99cBx5cmsNzsPf_Y3Y0JeQErWIs00M7m1AFBUxkScxSzVgvvaGqXalvnTZD4XR0fp1y3yq6-FQVplHxNdoDalxj3yNxyiKuDjNOHvV98Z3hqFp6v9FRqtWUzs6U-AbPW78Sf4f19yfvB58fGQdbcKMB2GvGHWJDYKA615FsbacJPHKrY6Drj2bWp1pEyYJxzwvY5FbgSM-iKPwpxjp5QwALVXyNUQgBC61Yx_Gw4tksRd8AOACWAZ5PGuRsdV6jm-CUPqPPgYGKe_kQfPZ4O_0uG581mX9g5u_Wcv7Da52a2v6ah1iDtkyxZ3yfVZxyC4R36PXVkoLXMKS1-qViuGidxQVRjqGC3sGD7V6xUCE0gFFLlxtKOx0dHkywdTntCyoKasLV22FQDNKSrEZgespdaDiraybWlrEKJd-9qa4r43PbGNwkqupaaVxeni8Ql8EThg9ZYq6liejjYLEmU2bJyDZGWbquzLY6lrDnyfLC7jhT4g20VZ2IeECj8IRSC44gpWI5FOoyjhxkYmisM4M8ojfm9kUnc93_HqkWM5dKt2hinBMKUzTOl7ZH94ZtV2PLlQ-hXarsRwCJq16qo6YH7YWEyOsAMjLFLTxCN7G5IQxvTmcG_GsgujtTyzYY88H4bxSaQGFrZco0wkABaIIPbIbus1w7wDwOOgPfLI696NzpT_-0c9unguz8jO4WI2ldPxfPKY3ODOq5ESuke2m2ptn5Br-kezrKunLj5QIi_Zvf4AXZSiOg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFFVceD8MBRYJxIFaldevNRKCQBsRpYQK9dCbtd5dS5FaO9gOqD-Nv8EvYmb9KKlEbz1wjHY82Tjz3P1mBuAlumQlkky5OjcGExSZuSLKIjdRgnvKaCnblvkH8Xwujo-Tww341dfCEKyyt4nWUOtS0Rn5LkerivlxEvPdvINFHO5N3i-_uzRBim5a-3EarYjMzNlPTN_qd9M9_K9fcT7ZP_r02e0mDLgqCHjjGh2bMPCV4lkQKc11HsnIqMjnyjOJUaHUQR5zzPVVJHItcNUTeRjknLqmBD6yvQabMcYYwQg2P-7PD78NVxhxbMf9YPqESRp69a5ix9btWfSJS0B61DgUVW_NK170DX85xwu3tdYJTm79x6_vNtzsIm82blXlDmyY4i5sfemwBffg99QWjLIyZxgUM7lcuuTiNZOFZhbr4p7gp3q1pJQFnQQj1BzrAG5sPPv6QZenrCyYLmvDFm1tQHNGDKkNgtuC7pFFW_O2MDUSsa6xbc3oRJydmkZSjddCscrQduliBb8IVbN6yySz-E8LqEWKMhuO1JGyMk1V9oWzzLYNvg9HV_FCH8CoKAvzCJjw_ED4gksuMU4JVRKGMdcm1GEURJmWDni9wKWq6wZPQ0lO0qGPtRXSFIU0tUKaeg68GZ5Ztr1QLqV-TXKckqFEzkp29R64P2o5lo6pNyOGr0nswPYaJRo4tb7ci3TaGdg6PZdnB14My_QkgQYLU66IJhSYMAg_cuBhq0HDvn3M1JF76MBOr1LnzP_9ox5fvpfnsIValR5M57MncINbBSes6DaMmmplnsJ19aNZ1NWzzlgwSK9Yv_4AfDisTw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+the+app-based+and+nurse-led+supportive+care+program+AKO%40dom+on+dose+intensity+of+oral-targeted+therapies+in+patients+with+metastatic+renal+cell+cancer%3A+a+multicentric+observational+retrospective+study&rft.jtitle=Supportive+care+in+cancer&rft.au=Gaillard%2C+Victor&rft.au=Lhuillier%2C+Albane&rft.au=Bigot%2C+C%C3%A9cile&rft.au=Pierard%2C+Laure&rft.date=2022-08-01&rft.pub=Springer&rft.issn=0941-4355&rft.volume=30&rft.issue=8&rft.spage=6583&rft_id=info:doi/10.1007%2Fs00520-022-07088-1&rft.externalDocID=A707943197 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0941-4355&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0941-4355&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0941-4355&client=summon |